Title |
Cancer Center Support Grant
|
Institution |
FRED HUTCHINSON CANCER RESEARCH CENTER, SEATTLE, WA
|
Principal Investigator |
GILLILAND, D
|
NCI Program Director |
Shafik
|
Cancer Activity |
Multidisciplinary
|
Division |
OCC
|
Funded Amount |
$225,000
|
Project Dates |
01/01/1997 - 12/31/2019
|
Fiscal Year |
2018
|
Project Type |
Grant
|
Research Topics w/ Percent Relevance |
Cancer Types w/ Percent Relevance |
Cancer (100.0%)
Aging (3.0%)
Basic Behavioral and Social Science (1.0%)
Behavioral and Social Science (5.0%)
Biochemical Epidemiology (11.0%)
Bioengineering (6.0%)
Bone Marrow Transplantation (6.0%)
Cancer Survivorship (8.0%)
Chemoprevention (4.0%)
Chemotherapy (9.0%)
Childhood Cancers (9.0%)
Depression Research (1.0%)
Diabetes (2.0%)
Digestive Diseases (24.0%)
Genetic Testing (1.0%)
Herpes - Other (1.0%)
Metastasis (5.0%)
Nuclear Magnetic Resonance Imaging (NMR) (2.0%)
Organ Transplantation Research (8.0%)
Smoking Behavior (2.0%)
Surgery (1.0%)
|
Anus (1.0%)
Brain (6.0%)
Breast (12.0%)
Cervical Cancer (4.0%)
Childhood Leukemia (2.0%)
Colon/Rectum (15.0%)
Esophagus (3.0%)
Head and Neck (1.0%)
Kaposi Sarcoma (2.0%)
Leukemia (10.0%)
Liver Cancer (2.0%)
Lung (6.0%)
Melanoma (1.0%)
Multiple Myeloma (2.0%)
Neuroblastoma (3.0%)
Non Hodgkins Lymphoma (4.0%)
Ovarian Cancer (5.0%)
Pancreas (4.0%)
Prostate (4.0%)
Sarcoma (2.0%)
Vaginal (1.0%)
Vascular Disease (1.0%)
|
Research Type |
Resources & Infrastructure Related to Biology
Resources and Infrastructure Related to Etiology
Resources and Infrastructure Related to Prevention
Resources and Infrastructure Related to Detection, Diagnosis, or Prognosis
Resources and Infrastructure Related to Treatment and the Prevention of Recurrence
Resources and Infrastructure Related to Cancer Control, Survivorship, and Outcomes Research
|
Abstract |
? DESCRIPTION (provided by applicant): The Fred Hutchinson/University of Washington Cancer Consortium (Consortium) brings together more than 450 members with research interests in basic, clinical and public health sciences related to cancer. The goal of the Consortium is the elimination of cancer through more effective prevention, diagnostics, and treatment, deriving from fundamental insights into the biology of the disease. The extensive interdisciplinary collaboration between the partner institutions in the cancer research disciplines of basic, clinical, and public health sciences affords new opportunities to reduce suffering and mortality from cancer. Over the next grant period, the Consortium will seek to: (1) Continue its leadership in cellular immunotherapy, with the goal of making this therapeutic platform the standard of care for many malignancies; (2) Build on our outstanding strengths in cancer basic biology to increase collaborative translational research, including using genomic and epigenomic technologies to develop effective prognostic tests for solid tumor cancers, applying protein engineering to novel cancer therapeutics, and developing robust mouse models of cancer for rapid screening of drug response prior to therapeutic intervention; (3) Expand our pioneering efforts to reduce the global burden of cancer through translational research on infection-related malignancies, application of global disease surveillance data, and unique international partnerships in Africa (Uganda and South Africa) and more recently China to establish robust platforms for improving our understanding of the spectrum of cancer biology and disease worldwide; (4) Lead research that supports provision of efficient, effective and cost-effective cancer care through research in health economics, cancer outcomes and comparative effectiveness; and (5) Lead population-based research to uncover new insights into the link between obesity and cancer, and to reduce disparities in cancer risk, outcomes and access to care in underserved populations." |